| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b0c198757da18cf77dfbdcef00abb70 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5767 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
1999-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94b405d722230b7440f97162e90ca993
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fa096794c0ec4c8077573dd78e6d7e2 |
| publicationDate |
2001-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1133692-A1 |
| titleOfInvention |
Methods of identifying viral therapeutics |
| abstract |
A method for identifying a substance for affecting a viral infection is described. The method comprises: a) providing a lipid globule targeting sequence, as a first component; b) providing a lipid globule, as a second component; c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and d) determining whether the substance disrupts the interaction between the first and second components; wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof. |
| priorityDate |
1998-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |